J3590 HCPCS code: Unclassified biologics
J3590 is the HCPCS Level II code for unclassified biologics. In 2024 Medicare paid an average of $354.51 per service for J3590 across 253,780 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume fell 40% from 2022 to 2024 (424,689 to 253,780 services). In 2024, about 2,409 clinicians billed Medicare for J3590 for 43,565 beneficiaries; Washington, Ohio, Florida accounted for 39% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2003-01-01 |
| Last action effective | 2003-01-01 |
Who bills J3590 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 2,409 |
| Medicare beneficiaries | 43,565 |
| States with claims | 49 |
| Share of services in top 3 states (Washington, Ohio, Florida) | 39% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3590, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 424,689 | 50,975 | $354.65 | $282.17 |
| 2023 | 236,032 | 37,371 | $278.16 | $220.70 |
| 2024 | 253,780 | 43,565 | $446.82 | $354.51 |
States with the most J3590 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Washington | 41,915 | $11.07 |
| Ohio | 31,037 | $251.20 |
| Florida | 25,763 | $130.42 |
| Michigan | 16,957 | $127.24 |
| Indiana | 14,926 | $75.62 |
Medicare policy articles for this code
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
- A52451: Billing and Coding: Ranibizumab, Aflibercept and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
- A54880: Billing and Coding: Additional Claim Documentation Requirements for Not Otherwise Classified (NOC) Drugs and Biological Products with Specific FDA Label Indications (Palmetto GBA (MAC - Part A, MAC - Part B))
- A55913: Billing and Coding: Hospital Outpatient Drugs and Biologicals Under the Outpatient Prospective Payment System (OPPS) (Palmetto GBA (MAC - Part A))
- A56380: Billing and Coding: Rituximab (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (1,189 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C83.30 | Diffuse large B-cell lymphoma, unspecified site | 2 |
| C83.31 | Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck | 2 |
| C83.390 | Primary central nervous system lymphoma | 2 |
| C83.398 | Diffuse large B-cell lymphoma of other extranodal and solid organ sites | 2 |
| C83.3A | Diffuse large B-cell lymphoma, in remission | 2 |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites | 2 |
| C83.79 | Burkitt lymphoma, extranodal and solid organ sites | 2 |
| C83.80 | Other non-follicular lymphoma, unspecified site | 2 |
| C83.81 | Other non-follicular lymphoma, lymph nodes of head, face, and neck | 2 |
| C83.89 | Other non-follicular lymphoma, extranodal and solid organ sites | 2 |
Showing 10 of 1,189. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J3590
- 2003-01-01: J3590 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3590?
J3590 is the HCPCS Level II code for unclassified biologics. Short descriptor: "Unclassified biologics".
How much does Medicare pay for J3590?
In 2024, the average Medicare payment was $354.51 per service (average allowed $446.82).
Does Medicare cover J3590?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J3590?
Medicare policy articles that cite J3590 list 1,189 covered ICD-10-CM diagnosis codes across 5 articles. The most cited include C83.30 (Diffuse large B-cell lymphoma, unspecified site), C83.31 (Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck), C83.390 (Primary central nervous system lymphoma). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
Related J35 codes
- J3520 — Edetate disodium, per 150 mg
- J3530 — Nasal vaccine inhalation
- J3535 — Drug administered through a metered dose inhaler
- J3570 — Laetrile, amygdalin, vitamin b17
- J3591 — Unclassified drug or biological used for esrd on dialysis
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3590
- Watch J3590 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3590
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.